US stocks moving | Moderna continues to rise nearly 7% pre-market, advancing multiple early-stage studies related to hantavirus vaccines

```htmlGlonghui May 11｜Moderna (MRNA.US) continued to rise nearly 7% in pre-market trading, reaching $58.1. Last Friday, the stock closed up nearly 12%. In terms of news, Moderna disclosed that it is advancing multiple early-stage studies related to the hantavirus vaccine. In a statement, the company said it had previously conducted early-stage vaccine research targeting hantavirus with the U.S. Army Medical Research Institute of Infectious Diseases. In addition, the company is cooperating with the Vaccine Innovation Center at Korea University College of Medicine to develop a potential immune protocol. The related research started before the recent outbreak on the ‘Hondius’ cruise ship.```